SCHEMBL24007247

SCHEMBL24007247

CC(C)(C#N)c1cc(N)nn1[C@@H]1CCOC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.39
CREBBP Q92793 1/20 0.39
MAP3K12 Q12852 4/20 0.34
CNR2 P34972 3/20 0.34
CNR1 P21554 1/20 0.34
SRC P12931 5/20 0.33
PI4KB Q9UBF8 6/20 0.32
KDR P35968 5/20 0.32
PIK3CA P42336 5/20 0.32
PIK3CD O00329 4/20 0.32
ABL1 P00519 4/20 0.32
EGFR P00533 4/20 0.32
HCK P08631 4/20 0.32
PIK3CB P42338 4/20 0.32
MTOR P42345 4/20 0.32
PIK3CG P48736 4/20 0.32
EPHB4 P54760 4/20 0.32
PRKDC P78527 4/20 0.32
RET P07949 1/20 0.32
FLT3 P36888 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24007404 1.00 BRD4 (0.39) BRD4CREBBPMAP3K12CNR2CNR1
SCHEMBL24007495 0.92 CNR2 (0.37) BRD4CREBBPMAP3K12CNR2CNR1
SCHEMBL24816262 0.86 BRD4 (0.39) BRD4CREBBPMAP3K12CNR2CNR1
SCHEMBL24007277 0.85 CNR2 (0.36) MAP3K12CNR2SRCPI4KBKDR
SCHEMBL24007026 0.85 CNR2 (0.36) MAP3K12CNR2SRCPI4KBKDR
SCHEMBL24815073 0.85 CNR2 (0.36) MAP3K12CNR2SRCPI4KBKDR
SCHEMBL26011686 0.85 BRD4 (0.39) BRD4CREBBPMAP3K12CNR2CNR1
SCHEMBL26012741 0.84 BRD4 (0.38) BRD4CREBBPMAP3K12CNR2CNR1
SCHEMBL25746243 0.83 MAP3K12 (0.39) MAP3K12CNR2SRCPI4KBKDR
SCHEMBL25746248 0.83 MAP3K12 (0.39) MAP3K12CNR2SRCPI4KBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 US disclosed
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-20220411403-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2022-12-29 US disclosed
WO-2022140527-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2022-06-30 WO disclosed
WO-2021226261-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411403-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B BRD4 53/4885CREBBP 421/4885MAP3K12 516/4885
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B BRD4 53/4885CREBBP 421/4885MAP3K12 516/4885
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors JAK2, JAK3, STAT5B BRD4 53/4885CREBBP 421/4885MAP3K12 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.